New Data at ASCO, EHA Reinforce clonoSEQ's 'Gold Standard' Role in Blood Cancer Testing
ADPT sits 69% above its 52-week low of $8.98.
Summary
Adaptive Biotechnologies announced that its clonoSEQ MRD test will be featured in 33 presentations, including a plenary session, at the ASCO and EHA 2026 conferences. The data reinforces clonoSEQ's role as the 'gold standard' for assessing measurable residual disease across multiple hematologic malignancies, including multiple myeloma, CLL, ALL, and lymphoma. This strong showing at major medical conferences validates the product's clinical utility, strengthens its competitive position, and supports its increasing incorporation into both research and clinical practice.
At the time of this announcement, ADPT was trading at $15.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $8.98 to $20.76. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.